Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jul 2018 · 1 min read
In brief
In brief
Retrospective study of 12 pediatric patients with completely resected hepatocellular carcinoma demonstrates excellent outcomes with surgery alone, without adjuvant chemotherapy. Seven patients underwent liver transplantation (five exceeding Milan criteria), five had partial hepatectomy; all remain disease-free at median 54-month follow-up.
Written by the GCMD Library team from the article.
Statements in this article
Complete surgical resection remains the mainstay of therapy for hepatocellular carcinoma.
Hepatocellular carcinoma is often chemoresistant.
Twelve patients with median age 12 years (range 1-17 years) with upfront resected Evans stage I hepatocellular carcinoma were treated with surgical intervention alone.
Four patients had hepatocellular carcinoma without identifiable risk factors, including 2 with fibrolamellar variant, 1 with early hepatocellular carcinoma arising in focal nodular hyperplasia, and 1 with well-differentiated hepatocellular carcinoma.
Four patients had early or well-differentiated hepatocellular carcinoma in the context of portosystemic shunts, including 2 with Abernethy malformation and 2 with mesocaval shunt and portal vein thrombosis.
Four patients had moderate to well-differentiated hepatocellular carcinoma in the context of pre-existing liver disease with cirrhosis, including 2 with progressive familial intrahepatic cholestasis type 2, 1 with alpha-1 antitrypsin deficiency, and 1 with Alagille syndrome.
Seven patients underwent liver transplantation, including 5 with multifocal disease and 2 with solitary tumors.
Five patients exceeded Milan criteria by imaging.
Five patients underwent complete resection consisting of 2 segmentectomies and 3 hemihepatectomies.
Ten patients received no adjuvant chemotherapy.
All patients are alive without evidence of disease with a median follow-up of 54.1 months (range 2 months or more).